Trial Profile
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab for Treatment of Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Mannitol
- Indications Glioblastoma
- Focus Therapeutic Use
- 23 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Jun 2022 Planned End Date changed from 1 Feb 2022 to 1 Dec 2023.
- 02 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Feb 2022.